What is Arecor Therapeutics plc's (AREC.L) StockRank?

MoatMap's StockRank for Arecor Therapeutics plc (AREC.L) is 59/100, with a Hold signal. This is a composite score combining Quality (65), Value (51), and Momentum (33) factor ranks across MoatMap's 20,000+ stock universe.

Does Arecor Therapeutics plc have an economic moat?

Arecor Therapeutics plc (AREC.L) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Arecor Therapeutics plc a buy, hold, or sell?

MoatMap's current signal for Arecor Therapeutics plc (AREC.L) is Hold, based on a StockRank of 59/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Arecor Therapeutics plc in?

Arecor Therapeutics plc (AREC.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AREC.L

HOLDREMOVE

Arecor Therapeutics plc · Healthcare · United Kingdom · $34M · Avg Vol: $22K/d

StockRank

P/E (TTM)

31.3x

ROE

15.8%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Arecor Therapeutics is a micro-cap formulation technology company. While it has a high quality score, it is pre-profit and lacks the commercial scale and immediate macro tailwinds required for our concentrated fund.

COMPANY DESCRIPTION

Arecor Therapeutics plc is a globally focused biopharmaceutical company that utilizes its proprietary Arestat formulation technology platform to enhance existing therapeutic proteins and peptides. The platform enables the development of superior, patent-protected reformulations of established drugs, such as ultra-rapid acting insulins, with reduced development risk. The company operates a dual-model business, developing its own high-value clinical pipeline while generating near-term revenues through technology licensing partnerships.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	3M	6M	2M	2M	-10.7%
EPS	—	-0.43	-0.00	-0.42	0.03	—
Shares	—	31M	31M	38M	38M	+23.3%
Debt	0	386,645	453,770	311,464	131,567	-30.2%
Equity	—	23M	13M	7M	9M	-28.2%
Op CF	—	-14M	-8M	-13M	-3M	—
Inv CF	—	-11M	9M	2M	3M	—
Fin CF	—	7M	-241,653	8M	-198,692	—

PRICE (1M)-5.3%

SMA 50SMA 200

$0.84

RSI (14)

31.6

52W High

$1.34

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

15.5%85.7

ROE

15.8%83.9

GP/Assets

15.5%35.9

Op. Margin

-236.0%13.2

FCF/Assets

59.6%98.8

Piotroski

—28.7

Int. Cover

50.0x91.5

D/E Ratio

0.02x85.1

Current Ratio

4.78x69.6

Value

P/E (TTM)

31.3x35.2

EV/EBITDA

-4.5x72.0

P/FCF

3.9x94.2

P/B

3.7x32.5

P/S

13.8x21.5

Div Yield

—N/A

Momentum

52W High %

63%44.6

RS 6M

-29%44.0

SMA 50/200

0.90x34.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-664%0.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$34M

P/E (Forward)

-5.5x

Gross Margin

73.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AREC.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AREC.L	Arecor Therapeutics plc(you)	$34M	59	HOLD
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
IXI.L	IXICO plc	$25M	29	SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
BVXP.L	Bioventix PLC	$117M	96	STRONG BUY
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL
SCLP.L	Scancell Holdings plc	$333M	37	HOLD

Peer medians: ROE -1.8% · P/E 26.9x · Gross margin 50.8%

Arecor Therapeutics plc (AREC.L) — Stock Score Summary

Arecor Therapeutics plc (AREC.L) has a MoatMap StockRank of 59/100 based on Quality (65/100), Value (51/100), and Momentum (33/100) factor scores. The current signal is HOLD. Arecor Therapeutics is a micro-cap formulation technology company. While it has a high quality score, it is pre-profit and lacks the commercial scale and immediate macro tailwinds required for our concentrated fund.

Key Financial Metrics

Price	$0.84
Market Cap	$34M
P/E (TTM)	31.25
P/E (Forward)	-5.54
Price/Book	3.65
Return on Equity	15.8%
Return on Invested Capital	15.5%
Debt/Equity	1.52
Gross Margin	73.9%
Operating Margin	-236.0%
Free Cash Flow	$9M

Arecor Therapeutics plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Arecor Therapeutics plc’s (AREC.L) StockRank?: MoatMap’s StockRank for Arecor Therapeutics plc (AREC.L) is 59/100, with a Hold signal. It is a composite of Quality (65), Value (51), and Momentum (33) factor ranks across MoatMap’s 20,000+ stock universe.
Does Arecor Therapeutics plc have an economic moat?: Arecor Therapeutics plc (AREC.L) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Arecor Therapeutics plc a buy, hold, or sell?: MoatMap’s current signal for Arecor Therapeutics plc (AREC.L) is Hold, based on a StockRank of 59/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Arecor Therapeutics plc in?: Arecor Therapeutics plc (AREC.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).